Response Genetics, Cancer Genetics deal

Cancer Genetics will acquire substantially all the assets of fellow cancer diagnostic company Response Genetics for $7 million in cash and $7 million in Cancer Genetics shares. In connection with the deal, Response Genetics filed for Chapter 11 bankruptcy. The deal includes ResponseDX-Lung, ResponseDX-Gastric, ResponseDX-Colon and ResponseDX-Melanoma tests for therapy selection in lung, gastric and colon cancer and melanoma patients; and the ResponseDX-Tissue of Origin test to identify the primary site of unidentifiable tumors. ...